Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification

Eur J Ophthalmol. 2020 Mar;30(2):293-298. doi: 10.1177/1120672118817997. Epub 2018 Dec 10.

Abstract

Aim: To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throughout the first 24 h following uncomplicated phacoemulsification cataract surgery.

Patients and methods: A total of 62 patients who underwent phacoemulsification cataract surgery were included in this prospective randomized comparative case series. The brinzolamide-brimonidine fixed combination group (34 eyes) was administered a single dose of brinzolamide-brimonidine fixed combination immediately after phacoemulsification. No treatment was administered in the control group (28 eyes). Intraocular pressure was measured 1 day before surgery (baseline) and at 6, 12 and 24 h postoperatively.

Results: The brinzolamide-brimonidine fixed combination group had significantly lower intraocular pressure at 6, 12 and 24 h after phacoemulsification compared to baseline (p < 0.0001 for all comparisons), while in control group, intraocular pressure was significantly higher at 6 and 12 h after surgery compared to baseline (p < 0.001 and p < 0.0001, respectively). In control group, an intraocular pressure elevation ⩾ 5 mm Hg was noted in 32.4% of the eyes at 6 and 12 h and in 5.9% of eyes at 24 h after surgery, while in brinzolamide-brimonidine fixed combination group, only 8.8% of the eyes at 6 h postoperatively had such an intraocular pressure elevation.

Conclusion: The administration of a single drop of brinzolamide-brimonidine fixed combination effectively prevented intraocular pressure elevations and intraocular pressure spikes during the first 24 h after uneventful phacoemulsification.

Keywords: Brinzolamide–brimonidine fixed combination; intraocular pressure; phacoemulsification.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adrenergic alpha-2 Receptor Agonists / therapeutic use*
  • Aged
  • Aged, 80 and over
  • Brimonidine Tartrate / therapeutic use*
  • Carbonic Anhydrase Inhibitors / therapeutic use*
  • Double-Blind Method
  • Drug Combinations
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Male
  • Middle Aged
  • Ocular Hypertension / etiology
  • Ocular Hypertension / prevention & control*
  • Phacoemulsification*
  • Postoperative Complications / prevention & control
  • Prospective Studies
  • Sulfonamides / therapeutic use*
  • Thiazines / therapeutic use*
  • Tonometry, Ocular

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Carbonic Anhydrase Inhibitors
  • Drug Combinations
  • Sulfonamides
  • Thiazines
  • Brimonidine Tartrate
  • brinzolamide